ARCHIVES

FDA Approves Xtandi For Late-Stage Castration-Resistant Prostate Cancer

This article is from The Cancer Letter archive.

Vol. 35 No. 8 | August 31, 2012

Download PDF Visit The Full Archive

Related Articles

Sponsors Wanted: FDA Offers Incentives For Pediatric Oncology Drug Development.

March 10, 2000

FDA Approves Gleevec For First Line Rx Of CML

January 31, 2003

NCI Advisory Group, Other Cancer Meetings For Sept,. Oct,. Future

August 25, 1989

NCI Chips In $2 Million For AACR Meeting; Advisors, Senior Staff Not Consulted.

June 20, 2003

Funding Opportunity: Stand Up To Cancer Canada to Fund Two Dream Teams

October 17, 2014

Symposium Planned On Grantmanship

April 20, 1984